Routine upfront abciximab versus standard periprocedural therapy in patients undergoing primary percutaneous coronary intervention for cardiogenic shock: The PRAGUE-7 Study. An open randomized multicentre study

References

• Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005;294:448–54.
   PubMed Web of Science ®Google Scholar
• Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, . Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;241:625–34.
   Google Scholar
• Jeger RV, Radovanovic D, Hunziker PR, Pfisterer ME, Stauffer JC, Erne P, . Ten-year trends in the incidence and treatment of cardiogenic shock. Ann Intern Med. 2008;149:618–26.
   PubMed Web of Science ®Google Scholar
• Chan AW, Chew DP, Bhatt DL, Moliterno DJ, Topol EJ, Ellis SG. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol. 2002;89:132–6.
   PubMed Web of Science ®Google Scholar
• Giri S, Mitchel J, Azar RR, Kiernan FJ, Fram DB, McKay RG, . Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol. 2002;89:126–31.
   PubMed Web of Science ®Google Scholar
• Antoniucci D, Valenti R, Migliorini A, Moschi G, Trapani M, Dovellini EV, . Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol. 2002;90:353–7.
   PubMed Web of Science ®Google Scholar
• Gottdiener JS, Bednarz J, Devereux R, Gardin J, Klein A, Manning WJ, . American Society of Echocardiography recommendations for use of echocardiography in clinical trials. A report from the American Society of Echocardiography's guidelines and standards committee and the task force on echocardiography in clinical trials. J Am Soc Echocardiog. 2004;17: 1086–119.
   PubMed Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Harvey D. Universal definition of myocardial infarction. Eur Heart J. 2007;28:2525–2538.
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, . Acute kidney injury network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
   PubMed Web of Science ®Google Scholar
• Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med. 2008;168:987–95.
   PubMedGoogle Scholar
• Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, . Thrombolysis in myocardial infarction (TIMI) trial—phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11.
   PubMed Web of Science ®Google Scholar
• De Luca G, Suryapranata H, Stone G, Antoniucci D, Tcheng JE, Neumann FJ . Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. JAMA 2005;293:1759–65.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Antoniucci D, Kastrati A, Neumann FJ, Borentain M, Miglorini A, . Abciximab in primary coronary stenting of ST-elevation myocardial infarction: A European meta-analysis on individual patients’ data with long-term follow-up. Eur Heart J. 2007;28:443–9.
   PubMed Web of Science ®Google Scholar
• Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, . Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med. 2002;113:1–6.
   PubMed Web of Science ®Google Scholar
• Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP, . Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059–65.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Borentain M, Payot L, Collet JP, Thomas D. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percu taneous coronary intervention of acute ST-segment elevation myocardial infarction. JAMA 2004;292: 362–6.
   PubMed Web of Science ®Google Scholar
• Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: Quantitative review of randomized trials. Lancet 2006;367:579–88.
   PubMed Web of Science ®Google Scholar
• Ellis SG, Tendera M, de Belger MA, van Boven AJ, Widimsky P, Janssens L, . Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med. 2008;358:2205–17.
   PubMed Web of Science ®Google Scholar
• Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, . Long-term effectiveness of early administration of glykoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: Results of registry study in an ST-elevation myocardial infarction network. Eur Heart J. 2009;30:33–43.
   PubMedGoogle Scholar
• Huber K, Holmes DR Jr, van't Hof AW, Montalescot G, Aylward PE, Betriu GA, . Use of glykoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: Insight from the APEX-AMI Trial. Eur Heart J. 2010;31:1708–16.
   Google Scholar
• De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, . Early glycoprotein IIb-IIa inhibitors in primary angioplasty (EGYPT) cooperation: An individual patient data meta-analysis. Heart 2008;94:1548–58.
   PubMedGoogle Scholar
• De Luca G, Suryapranata H, Zijlstra F, van't Hof AW, Hoorntje JC, Gosselink AT, . Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2003;42:991–7.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Gibson CM, Lambrew CT, Shoultz DA, Levy D, French WJ, . Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283: 2941–7.
   PubMed Web of Science ®Google Scholar
• Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: Is the slope of the curve the shape of the future? JAMA 2005;293:979–86.
   PubMed Web of Science ®Google Scholar
• Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, . Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. The task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2008;29:2909–45.
   PubMed Web of Science ®Google Scholar
• Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, . Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I investigators. Circulation 1995;91:1659–68.
   PubMed Web of Science ®Google Scholar
• Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, López-Sendón J, . Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the global registry of acute coronary events (GRACE). Circulation 2004;109:494–9.
   PubMed Web of Science ®Google Scholar
• Wu AH, Parson L, Every NR, Bates R. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the second national registry of myocardial infarction (NRMI-2). J Am Coll Cardiol. 2002;40:1389–94.
   PubMed Web of Science ®Google Scholar